trending Market Intelligence /marketintelligence/en/news-insights/trending/gjC_QQbcG42HFDYHot8XoA2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Moody's: US Senate drug pricing bill ups social, financial risk for Big Pharma

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

Moody's: US Senate drug pricing bill ups social, financial risk for Big Pharma

Moody's believes the U.S. Senate Finance Committee's drug pricing legislation proposal creates social and financial risk for pharmaceutical companies like Amgen Inc., Gilead Sciences Inc. and AbbVie Inc. due to their high exposure to U.S. markets.

The rating agency said in an Aug. 7 report that the draft Senate bill, introduced July 23, would also target drugs with high price increases in both Medicare Part D and Part B, representing pharmacy- and provider-administered drugs respectively.

SNL Image

Drugs covered in Part D would have a greater risk, and as far as individual products, Moody's cited Sanofi's diabetes drug Lantus, Celgene Corp.'s cancer drug Revlimid and Bristol-Myers Squibb Co. and Pfizer Inc.'s heart drug Eliquis as those with the highest use under that section.

The Congressional Budget Office predicted that from Part D rebates alone, annual savings to the federal government would be more than $10 billion if the bill is enacted.

It would also reduce out-of-pocket costs for Medicare beneficiaries, which would come at the industry's expense in general, Moody's reported. Pharmaceutical executives from some of the biggest pharmaceutical companies have said the proposal punishes innovators.

"Regulators' and legislators' recent proposals to bring down the cost of drugs signal that drug price scrutiny remains a social risk for the U.S. pharmaceutical industry," Moody's Senior Vice President Michael Levesque said. "If enacted, proposals such as those allowing imports of certain drugs, or the bipartisan draft bill known as the Prescription Drug Pricing Reduction Act, would pressure prices and raise financial risks for the branded drug industry."

Companies with less dependence on U.S. markets — like Johnson & Johnson and Sanofi — would be less exposed to financial risk from the changes in the U.S., even if certain drugs in their portfolios are affected by Medicare coverage.

Moody's said the Senate's proposal would be more detrimental to pharmaceutical finances than the U.S. Health and Human Services' action plan to implement drug importation from Canada and other countries, as that would likely be a slower process and lead to more modest decreases.